1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression
2020
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI
Old Web
English
Sign In
Email Address
acemap@cs.sjtu.edu.cn
- CCF Conference Analysis
- Map Galaxy
- Academic Report
- What's New
© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.